Table 1.
Correlation of the clinico-pathological findings with PCR and in situ hybridization data.
| In situ Hybridization | PCR | |||||||
| EBV(+) | EBV(-) | p-value | EBV(+) | EBV(-) | p-value | |||
| N | N(%) | N(%) | N | N(%) | N(%) | |||
| Total | 160 | 11 (6.9) | 149 (93.1) | 151 | 73 (48.3) | 78 (51.7) | ||
| Sex | 118 | 0.162 | 109 | 0.236 | ||||
| Male | 9 (90) | 70 (64.8) | 39 (65) | 37 (75.5) | ||||
| Female | 1 (10) | 38 (35.2) | 21 (35) | 12 (24.5) | ||||
| Age distribution* | 117 | 0.795 | 108 | 0.256 | ||||
| 15–44 | 1 (10) | 10 (9.3) | 7 (11.7) | 3 (6.3) | ||||
| 45–54 | 2 (20) | 21 (19.6) | 7 (11.7) | 12 (25) | ||||
| 55–64 | 1 (10) | 25 (23.4) | 18 (30) | 11 (22.9) | ||||
| > 65 | 6 (60) | 51 (47.7) | 28 (46.6) | 22 (45.8) | ||||
| Anatomic localization | 157 | 0.432 | 126 | 0.893 | ||||
| Upper | 3 (27.3) | 23 (15.8) | 10 (17.5) | 11 (15.9) | ||||
| Intermediate | 3 (27.3) | 29 (19.9) | 9 (15.8) | 13 (18.8) | ||||
| Lower | 5 (45.4) | 94 (64.3) | 38 (66.7) | 45 (65.2) | ||||
| Lauren’s classification | 160 | 0.098 | 150 | 0.745 | ||||
| Intestinal | 10 (90.9) | 93 (62.4) | 49 (68.0) | 55 (70.5) | ||||
| Diffuse | 1 (9.1) | 56 (37.5) | 23 (31.9) | 23 (29.4) | ||||
| Tumor stage | 160 | 0.533 | 150 | 0.287 | ||||
| In situ | 1 (1.3) | 0 (0) | ||||||
| IA | 0 (0) | 4 (2.7) | 3 (4.1) | 3 (3.9) | ||||
| IB | 1 (9.1) | 14 (9.4) | 3 (4.1) | 10 (12.9) | ||||
| II | 1 (9.1) | 32 (21.5) | 11 (15.1) | 18 (23.4) | ||||
| IIIA | 2 (18.2) | 41 (27.5) | 18 (24.7) | 17 (22.1) | ||||
| IIIB | 4 (36.3) | 23 (15.4) | 16 (21.9) | 12 (15.6) | ||||
| IV | 3 (27.3) | 35 (23.5) | 21 (28.8) | 17 (22.1) | ||||
| Tumor differentiation | 156 | 0.497 | 118 | 0.663 | ||||
| Undifferentiated | 0 (0) | 1 (0.7) | 1 (1.9) | 0 (0) | ||||
| Poorly | 3 (30) | 58 (39.7) | 19 (35.2) | 25 (39.1) | ||||
| Moderately | 7 (70) | 70 (47.9) | 27 (50) | 29 (45.3) | ||||
| Well differentiated | 0 (0) | 17 (11.6) | 7 (12.9) | 10 (15.6) | ||||
*
ISH(+) group age average = 61.2 ; PCR(+) group age average = 61.53